Esperion Therapeutics, Inc. · NASDAQ:ESPR
Esperion Therapeutics — Q4 2025 Earnings Presentation
22 slides from Esperion Therapeutics's earnings presentation, Mar 10, 2026
Slide 1: Q4 and Full Year 2025 Earnings Presentation
Q4 and Full Year 2025 Earnings Presentation March 10, 2026 © 2026 Esperion Therapeutics, Inc. All rights reserved.
Slide 2: Forward-looking Statements & Disclosures
Forward-looking Statements & Disclosures This investor presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization and business development plans, current
Slide 3: CEO Commentary
CEO Commentary “2025 was a defining year for Esperion. We delivered strong growth in our U.S. cardiovascular franchise, broadened access and adoption among statin intolerant or statin-resistant patients and strengthened the durability of our business with important intellectual property and market a
Slide 4: Transformational Leap Forward
in Action: A Transformational Leap Forward Diversified Product Portfolio Reach Sustainable Profitability in 2026 Perfectly positioned to aggressively attack two of the largest cardiometabolic markets, Durable Cash Flows allowing us to further our mission of helping millions of patients worldwide Str
Slide 5: 2025 A Pivotal Year; the Strongest in Esperion's History
2025 A Pivotal Year; the Strongest in Esperion’s History FY 2025 U.S. NET RETAIL PRESCRIPTION YE 2025 PRODUCT SALES EQUIVALENTS Y/Y CASH & CASH EQUIVALENTS +38% Y/Y growth TOTAL REVENUE 5 © 2026 Esperion Therapeutics, Inc. All rights reserved.
Slide 6: Q4 2025: Delivering Consistently Strong Execution
Q4 2025: Delivering Consistently Strong Execution Q4 TOTAL REVENUE Q4 U.S. NET PRODUCT SALES +144% Y/Y growth ~38% Y/Y growth Increased unique HCPs Finalized agreements with five +11.3% prescribing NEXLETOL and generic manufacturers Retail Prescription NEXLIZET by 24% in 2025 Equivalents Q/Q 6 © 202
Slide 7: Bempedoic Acid: Partner-Led Expansion Outside the U.S.
Bempedoic Acid: Partner-Led Expansion Outside the U.S. Multi-Billion $ Global Opportunity Provides Additional Revenue Streams Europe, Asia & Australia & Japan Israel Canada South America New Zealand Daiichi Sankyo Europe / Otsuka Pharmaceutical Partner Neopharm Israel CSL Seqirus HLS Therapeutics Da
Slide 8: International Growth Continues at Strong Pace
International Growth Continues at Strong Pace 800,000 700,000 patients through December 2025 600,000 500,000 400,000 300,000 200,000 100,000 0 Note: Numbers are approximate and based on an internal calculation methodology and includes Germany, UK, Austria, Belgium, Switzerland, Italy, Ireland, Spain
Slide 9: Pipeline Advancement
ESPERION Pipeline Advancement
Slide 10: Proven Science, Innovative Pipeline
Proven Science, Innovative Pipeline Innovative Portfolio & Pipeline LEAD PRECLINICAL CLINICAL APPROVED / PRODUCT/PROGRAM EXPLORATORY LEAD ID OPTIMIZATION DEVELOPMENT DEVELOPMENT COMMERCIAL MILESTONES Cardiovascular Disease (LDL-C lowering / CV Risk reduction) NEXLETOL® Approved 2020 bempedoic acid E
Slide 11: Corstasis Therapeutics
ESPERION Corstasis Therapeutics
Slide 12: Corstasis Therapeutics Acquisition Overview
Corstasis Therapeutics Acquisition Overview Company Summary Transaction Summary • Lead asset, Enbumyst (bumetanide nasal spray), • Esperion to own global rights to Enbumyst and all FDA-approved in September 2025 for adults with pipeline assets edema associated with congestive heart failure, and hepa
Slide 13: What Makes Enbumyst Stand Out?
What Makes Enbumyst Stand Out? Developed in collaboration with cardiology experts to address unmet need for nasal option in loop- diuretic therapy Uniqueness Differentiation • First and only nasal spray diuretic • Cost savings based on differentiated pricing • Provides rapid absorption (bypassing GI
Slide 14: Congestive Heart Failure Hospitalizations
Congestive Heart Failure Hospitalizations 1 in 4 patients readmitted within 30 days, driving significant healthcare costs Greatest Expenditure for CHF Treatment Estimated to be $8-15B Annually with Most Common Cost Due to Need for IV Diuretic Treatment 4 Million Hospital ~67% of Admissions are for ~
Slide 15: Multi-Billion Dollar Annual US Market Opportunity
Multi-Billion Dollar Annual US Market Opportunity Revolutionizing Outpatient CHF Management 6.7M 2.1M $2,214 $4.6B CHF Patients Addressable Average Cost of Addressable Market CHF Episodes Enbumyst per CHF Opportunity Episode *$399/dose; assumes average of 5.55 doses per episode Goal of Therapy | Red
Slide 16: Financial Update
Financial Update Ben Halladay, Chief Financial Officer
Slide 17: FY 2026 Operating Expense Guidance
FY 2026 Operating Expense Guidance FY 2026 R&D Guidance $40 – 50 M • Reflects continued investment in U.S. commercial execution • Strong synergies between our product FY 2026 SG&A Guidance $185 – 205 M lines allows launch of Enbumyst with modest increases • Supports advancement of pipeline FY 2026 O
Slide 18: Strong Prescription Trend and Increasing Physician Adoption Continue to Drive Durable Revenue Growth
Strong Prescription Trend and Increasing Physician Adoption Continue to Drive Durable Revenue Growth Quarterly Franchise Retail Prescription Equivalents (RPE) Trend Weekly Franchise RPE Trend1 300,000 +11.3% 30,000 250,000 25,000 200,000 20,000 150,000 15,000 100,000 10,000 50,000 5,000 0 0 1/1/2021
Slide 19: Important Safety Information
Important Safety Information
Slide 20: Enbumyst Safety Information
Enbumyst Safety Information ENBUMYST is contraindicated in patients with anuria, who are in hepatic coma and have a history of hypersensitivity to bumetanide. ENBUMYST is a diuretic that may cause fluid, electrolyte, and metabolic abnormalities. Excessive fluid loss can lead to dehydration, decrease
Slide 21: NEXLETOL (bempedoic acid) Important Safety Information
NEXLETOL® (bempedoic acid) Important Safety Information NEXLETOL is indicated: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommen
Slide 22: NEXLIZET (bempedoic acid and ezetimibe) Important Safety Information
NEXLIZET® (bempedoic acid and ezetimibe) Important Safety Information NEXLIZET is indicated: • as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including HeFH. • bempedoic acid, a component of NEXLIZET, is indicated to reduce the risk of major adverse cardiovas
Esperion Therapeutics — Q4 2025 Earnings Presentation on 6ix